Showing results (151-160 of 331) with videos related to
Sort By:
Pageof 34
Journal for Immunotherapy of Cancer|October 26, 2016
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunctionBridgette A Kanz, Megan H Pollack, Romany Johnpulle, et al.The Oncologist|November 20, 2024
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitorsJarushka Naidoo, Douglas B Johnson, Charlotte Doran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation ProgramAbdul Rafeh Naqash, Melissa Y Y Moey, Xiao-Wei Cherie Tan, et al.Cancer Immunology Research|February 4, 2014
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapyDouglas B Johnson, Erika K Wallender, Daniel N Cohen, et al.Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, et al.The Oncologist|May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with MelanomaAllison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.Nature Nanotechnology|January 22, 2019
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapyDaniel Shae, Kyle W Becker, Plamen Christov, et al.Cell|September 12, 2015
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceWilly Hugo, Hubing Shi, Lu Sun, et al.Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.Pageof 34